The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Takeda will seek an external partner to leverage its cell therapy platform technologies
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
